EC
DFTX

EntryPoint Capital’s Definium Therapeutics DFTX Stock Holding History

EntryPoint Capital’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-20,219
Closed -$271K – 857
2025
Q4 		$271K Buy
+20,219
New +$250K 0.11% 406
2025
Q2 		– Sell
-22,708
Closed -$133K – 731
2025
Q1 		$133K Buy
+22,708
New +$163K 0.06% 602

Other funds holding DFTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

EntryPoint Capital's DFTX Position: Q1 2026 in Review

EntryPoint Capital sold out of Definium Therapeutics (DFTX) in Q1 2026, closing a stake of 20,219 shares — an estimated $271K sold.

EntryPoint Capital first reported a position in DFTX in Q1 2025 and held it in 2 quarters. The position peaked at $271K in Q4 2025. 247 funds tracked by Wall St. Rank hold DFTX as of Q1 2026.

  • EntryPoint Capital reported no remaining Definium Therapeutics position as of Q1 2026 after selling out during the quarter.
  • EntryPoint Capital sold 20,219 Definium Therapeutics shares in Q1 2026, an estimated $271K.
  • EntryPoint Capital first reported a position in Definium Therapeutics in Q1 2025 and held it in 2 quarters.
  • EntryPoint Capital's Definium Therapeutics position peaked at $271K in Q4 2025.
  • 247 funds tracked by Wall St. Rank held Definium Therapeutics as of Q1 2026.

Based on EntryPoint Capital's 13F filing for Q1 2026, filed 14 May 2026.